drugset / Trial / NCT01425190

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

NCT01425190

Phase 1 Terminated 16 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.

Timeline

Start
2012-01-04
Primary completion
2013-03-20
Completion
2013-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Boceprevir Small molecule 11.4 mg/kg Oral